Briefing: Sarepta Therapeutics shares rise on early promise for rare disease drugs
Strategic angle: Sarepta Therapeutics’ next crop of medicines for muscular dystrophy appear to be safe and effective in early clinical trials, the company said.
Strategic angle: Sarepta Therapeutics’ next crop of medicines for muscular dystrophy appear to be safe and effective in early clinical trials, the company said.